Literature DB >> 12369885

Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases.

Andrew J Thompson1, Colin J Barrow.   

Abstract

The accumulation of proteinaceous deposits has been recognised to occur in several neurodegenerative conditions including Prion diseases, Alzheimer's disease, Parkinson's disease, and Huntington's disease. Over the last two decades interest in these conditions has increased markedly, fueled partially by an increasing prevalence of these diseases in the Western world. Evidence indicates that anomalous protein misfolding and aggregation, with an accompanying "toxic gain of function" is central to the neuropathogenesis of these diseases. An increased understanding of the similarities and differences in the production, aggregation and accumulation of the respective proteins involved in these diseases, and the associated mechanisms of neurodegeneration, should aid in the development of new therapeutic agents to treat this group of related disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369885     DOI: 10.2174/0929867023369123

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Theoretical model of prion propagation: a misfolded protein induces misfolding.

Authors:  Edyta Małolepsza; Michal Boniecki; Andrzej Kolinski; Lucjan Piela
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

2.  Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein.

Authors:  Agya K Frimpong; Rinat R Abzalimov; Vladimir N Uversky; Igor A Kaltashov
Journal:  Proteins       Date:  2010-02-15

3.  Structural requirements for VAP-B oligomerization and their implication in amyotrophic lateral sclerosis-associated VAP-B(P56S) neurotoxicity.

Authors:  SoHui Kim; Sónia S Leal; Daniel Ben Halevy; Cláudio M Gomes; Sima Lev
Journal:  J Biol Chem       Date:  2010-03-05       Impact factor: 5.157

4.  Is type 2 diabetes an amyloidosis and does it really matter (to patients)?

Authors:  G J S Cooper; J F Aitken; S Zhang
Journal:  Diabetologia       Date:  2010-03-13       Impact factor: 10.122

Review 5.  Hsp104 and prion propagation.

Authors:  Nina V Romanova; Yury O Chernoff
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

6.  Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?

Authors:  Manfred Windisch; Birgit Hutter-Paier; Edith Schreiner; Robert Wronski
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 7.  Stress and prions: lessons from the yeast model.

Authors:  Yury O Chernoff
Journal:  FEBS Lett       Date:  2007-05-08       Impact factor: 4.124

8.  Optimal therapy in Gaucher disease.

Authors:  Ozlem Goker-Alpan
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

9.  A transmissible cytotoxic activity isolated from a patient with brain ischemia causes microglial cell activation and dysfunction.

Authors:  F Beretti; V Cenacchi; M Portolani; A Ardizzoni; E Blasi; C Cermelli
Journal:  Cell Mol Neurobiol       Date:  2007-03-23       Impact factor: 4.231

Review 10.  Huntington's disease: the past, present, and future search for disease modifiers.

Authors:  Erin B D Clabough
Journal:  Yale J Biol Med       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.